Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Spira

Showing results (21-30 of 91) with videos related to

Pageof 10
Sort By:
JCO Precision Oncology|April 5, 2024
Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With <i>KRAS</i><sup>G12C</sup>-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature ReviewJia Luo, Narjust Florez, Anjali Donnelly, et al.
Lung Cancer (Amsterdam, Netherlands)|July 22, 2021
A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type diseaseAlexander I Spira, Huakang Tu, Shivani Aggarwal, et al.
Investigational New Drugs|June 14, 2013
Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trialCraig Reynolds, Alexander I Spira, Larry Gluck, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2013
Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 studyDonald Richards, Darren M Kocs, Alexander I Spira, et al.
The Oncologist|September 24, 2025
Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trialSarina A Piha-Paul, Justin A Call, Alexander I Spira, et al.
AIDS Research and Human Retroviruses|May 1, 1995
Seroreactivity of analogous antigenic epitopes in glycoprotein 120 expressed in HIV-1 subtypes A, B, C, and DG A Pestano, K S Hosford, A I Spira, et al.
Oncology and Therapy|July 7, 2017
Efficacy and Safety Results of the Afatinib Expanded Access ProgramEdward S Kim, Balazs Halmos, Ingrid F Kohut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapySamir E Witta, Robert M Jotte, Katrik Konduri, et al.
Future Oncology (London, England)|December 16, 2021
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancerByoung Chul Cho, Enriqueta Felip, Hidetoshi Hayashi, et al.
Clinical Lung Cancer|August 25, 2011
A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancerAlexander I Spira, Nicholas O Iannotti, Michael A Savin, et al.
Pageof 10

Showing results (21-30 of 91) with videos related to

Sort By:
Pageof 10
JCO Precision Oncology|April 5, 2024
Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With <i>KRAS</i><sup>G12C</sup>-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature ReviewJia Luo, Narjust Florez, Anjali Donnelly, et al.
Lung Cancer (Amsterdam, Netherlands)|July 22, 2021
A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type diseaseAlexander I Spira, Huakang Tu, Shivani Aggarwal, et al.
Investigational New Drugs|June 14, 2013
Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trialCraig Reynolds, Alexander I Spira, Larry Gluck, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2013
Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 studyDonald Richards, Darren M Kocs, Alexander I Spira, et al.
The Oncologist|September 24, 2025
Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trialSarina A Piha-Paul, Justin A Call, Alexander I Spira, et al.
AIDS Research and Human Retroviruses|May 1, 1995
Seroreactivity of analogous antigenic epitopes in glycoprotein 120 expressed in HIV-1 subtypes A, B, C, and DG A Pestano, K S Hosford, A I Spira, et al.
Oncology and Therapy|July 7, 2017
Efficacy and Safety Results of the Afatinib Expanded Access ProgramEdward S Kim, Balazs Halmos, Ingrid F Kohut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapySamir E Witta, Robert M Jotte, Katrik Konduri, et al.
Future Oncology (London, England)|December 16, 2021
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancerByoung Chul Cho, Enriqueta Felip, Hidetoshi Hayashi, et al.
Clinical Lung Cancer|August 25, 2011
A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancerAlexander I Spira, Nicholas O Iannotti, Michael A Savin, et al.
Pageof 10